Study #2021-0274
A pilot study to assess changes in tumor biology following second-line treatment with pembrolizumab plus lenvatinib in patients with advanced pancreatic ductal adenocarcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab, lenvatinib
Description
This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Tumor, Adenocarcinoma
Study phase:
Phase I
Physician name:
Brandon Smaglo
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.